Company intelligence / Profile preview

Shanxi Qianyuan Pharmaceutical Group

Shanxi, China

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Shanxi Qianyuan Pharmaceutical Group is a commercial-stage, listed pharmaceutical company with a broad portfolio of approved generic and specialty drugs, primarily in small molecule oral solid dosage but with expansion into biologics and specialty health products. The company recently achieved consistency evaluation and NMPA approval for several generics such as fluoxetine hydrochloride capsules, and in 2023 launched domestic varenicline (smoking cessation drug), among China’s first manufacturers with full specs approved.

Therapeutic areas: ImmunologyNephrologyPsychiatryInfectious DiseasesPulmonologyCardiovascularOther
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Yeedozencom

Beyond the preview

Go deeper on Shanxi Qianyuan Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanxi Qianyuan Pharmaceutical Group.

Explore the full profile